<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725424</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-071</org_study_id>
    <nct_id>NCT02725424</nct_id>
  </id_info>
  <brief_title>Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer</brief_title>
  <acronym>MATCH</acronym>
  <official_title>A Randomized, Multicenter, Controlled Phase II Study to Compare Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gastric/Gastroesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized,phase II,open-label study, The purpose of this study is to determine the&#xD;
      optimal treatment for patients with locally advanced Gastric/Gastroesophageal Cancer&#xD;
      according to their Her-2 expression status.&#xD;
&#xD;
      The primary endpoint of this study: pathology response rate the second endpoints of this&#xD;
      study:pathology complete response rate R0 resection rate Progression-free survival ( PFS)&#xD;
      Disease -free survival (DFS) Overall survival(OS) Objective response rate(ORR) Adverse&#xD;
      event(AE)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (human epidermal growth factor receptor-2,HER2) positive patients: After 4 weeks of&#xD;
      SOX±Trastuzumab Neoadjuvant therapy, those who show CR(complete response) or PR(partial&#xD;
      response) by Resist evaluation will continue with D2 surgery , then 4cycles of&#xD;
      SOX±Trastuzumab Adjuvant chemotherapy, and 4cycles of Trastuzumab as maintenance therapy;&#xD;
      those who do not response to former therapy or progress, will be treated with&#xD;
      surgery,concurrent chemoradiotherapy,or 2th line chemotherapy.&#xD;
&#xD;
      (human epidermal growth factor receptor-2,HER2) negative patients： After 4 weeks of DOS or&#xD;
      SOX regimen as neoadjuvant therapy, those who show CR(complete response) or PR(partial&#xD;
      response) by Resist evaluation will continue with D2 surgery , then 4cycles of SOX adjuvant&#xD;
      chemotherapy, those who do not response to former therapy or progress, will be treated with&#xD;
      surgery,concurrent chemoradiotherapy,or 2th line chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>40 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Her2 Positive with SOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Her-2 Positive patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin 130 mg/m2, iv, d1 S-1 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), po,Bid， d1-14 Every 3weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Her-2 positive patients treated with Oxaliplatin plus S-1 and Trastuzumab Oxaliplatin : As Above S-1: As Above Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 Negative with SOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Her2 Negative patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin As Above S-1 As Above Every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Her-2 Negative patients treated with Docetaxel plus Oxaliplatin and S-1（DOS） Docetaxel 60 mg/m2, iv, d1 Oxaliplatin 100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Her-2 Positive patients with SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), po,Bid， d1-14 Every 3weeks.</description>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <arm_group_label>Her2 Negative with SOX</arm_group_label>
    <arm_group_label>Her2 Positive with SOX</arm_group_label>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Her-2 positive patients with SOXT Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), PO,BID， d1-14 Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks.</description>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>S-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>HER-2 Negative Patients：SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), PO,BID， d1-14 Every 3 weeks</description>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <arm_group_label>Her2 Negative with SOX</arm_group_label>
    <arm_group_label>Her2 Positive with SOX</arm_group_label>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks</description>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>S-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Pathologically confirmed gastric cancer or gastroesophageal junction adenocarcinoma&#xD;
&#xD;
          2. Significant HER-2 status:&#xD;
&#xD;
             positive defined as: immunohistochemistry+ + + or FISH（fluorescence in situ&#xD;
             hybridization） +. T negative define as: immunohistochemistry 0 ~ +, or&#xD;
             immunohistochemistry++, and FISH negative.&#xD;
&#xD;
          3. T3-4, any N stage of gastric cancer or gastro esophageal carcinoma (seventh edition of&#xD;
             AJCC).&#xD;
&#xD;
          4. Chemotherapy and radiotherapy naïve.&#xD;
&#xD;
          5. Aging from 18-70.&#xD;
&#xD;
          6. ECOG(Eastern Cooperative Oncology Group ) 0-1&#xD;
&#xD;
          7. Available Organ function: Neutrophils&gt;2g/L， Hemoglobin &gt;9g/L， Blood platelet &gt;100g/L；&#xD;
             Alanine aminotransferase（ALT） and Aspartate aminotransferase( AST) &lt;1.5 ULN(upper&#xD;
             limit of normal )； Total bilirubin(TBIL)&lt;1.0 ULN; Cr &lt;1.0 ULN&#xD;
&#xD;
          8. Left ventricular ejection fraction&gt;50%&#xD;
&#xD;
          9. Written informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Other pathology Type Other than adenocarcinoma, such as squamous cell carcinoma&#xD;
&#xD;
          2. History of allergies to drugs in the study&#xD;
&#xD;
          3. Intraperitoneal dissemination or distant metastasis&#xD;
&#xD;
          4. Digestive tract obstruction or uncontrollable recurrent bleeding ,clinical significant&#xD;
             ascites&#xD;
&#xD;
          5. Dysphagia&#xD;
&#xD;
          6. Any cause of cirrhosis&#xD;
&#xD;
          7. Cardiac function NYHA(New York Heart Association) &gt;I degrees&#xD;
&#xD;
          8. Previous myocardial infarction, unstable angina, stroke ,or uncontrollable Arrhythmia&#xD;
&#xD;
          9. Any surgical contraindication&#xD;
&#xD;
         10. Any chemotherapy or radiotherapy history&#xD;
&#xD;
         11. Any surgical resection history of gastric cancer&#xD;
&#xD;
         12. History of any other tumors except cured cutaneum carcinoma or carcinoma in situs of&#xD;
             cervix&#xD;
&#xD;
         13. Any contraindication for chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Ai Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

